C-Reactive Protein and Cardiovascular Risk Assessment
Emerging Role of Aldosterone in Cardiovascular Protection
Rosuvastatin: A New HMG-CoA Reductase Inhibitor for the Treatment of Dyslipidemia
Selected Non-Approved Use of Recombinant Human Erythropoietin, Part 1 of 2
Advances in Combination Cardiovascular Medications
Impact of Point-of-Care Barcode Technology on Medication Error Prevention
Slides, Files and Keeping Up
Summary of New Drug Applications and Biologic License Applications Submitted to the Food and Drug Administration
Pivotal/Significant Articles - Cardiology